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Substance abuse has twice the mortality in United States anaesthesia- than non-anaesthesia 
residents. Since no data exist, the primary objective of this cross-sectional study was to 
establish the prevalence of substance use in South African anaesthesia practitioners. 
Secondary objectives were to compare the prevalence in male and female practitioners, and 
in private- and state practice anaesthetists. Years of experience and level of training were 




Participants completed a self-administered, validated WHO questionnaire, run for ten days 
surrounding the 2018 South African Society of Anaesthesiologists (SASA) congress. All 
doctors practicing anaesthesia in South Africa were eligible. Recruitment was via an email 




A total of 1961 SASA members and 113 non-members (anaesthesiologists, registrars and 
non-specialists) were invited to participate (total 2074). There were 434 responses 
(response rate 20.9%, margin of error 4.18%); 364 were suitable for analysis. The most 
commonly lifetime-used substances were alcohol (92.8%), tobacco (42.3%), cannabis 
(34.7%), and sedatives (34.4%). Questionnaire scores defined low-, medium- and high-risk 
categories according to substance use during the previous 3 months. Sedative (12.6%) and 
alcohol (12.1%) users were deemed to be at moderate risk. The prevalence of opioid use 
was 1.9% (n=7). Prevalence of substance use was similar in male and female practitioners, 






The prevalence of current use of alcohol and sedatives is of major concern. A significant 
proportion of respondents were assessed to be at moderate risk of hazardous or harmful 
substance use. Gender and practice setting have little impact on substance use. Wellness 
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Substance abuse is linked to a more than three times higher incidence of suicide in young 
male anaesthesia practitioners, when compared with other physicians.1 The prevalence of 
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this behaviour should therefore be considered when analysing the complex topic of 
wellness in anaesthesiologists. 
 
In the United States, anaesthesiology residents are twice as likely to die from chemical 
dependency abuse than non-anaesthesia residents, 2 and are over-represented by a factor 
of seven at rehabilitation facilities. 2 The health care system in South Africa is unique and 
exists as a dichotomy of private and state care, each with its own unique challenges and 
stressors. No data exists for substance use in South African anaesthesia practitioners, either 
in private or state practice. 
 
The primary objective of this cross-sectional study was to describe the prevalence of 
substance use in anaesthesia practitioners in South Africa, in order to establish baseline 
data. The prevalence of lifetime- and of current use, defined as use within the previous 
three months, was determined. For this the purpose, a validated WHO questionnaire was 
used, which defines low-, moderate-, and high-risk categories for addiction to a substance. 
 
The secondary objectives were to compare the prevalence of substance use in male and 
female practitioners, and in private- and state practice. The number of years spent in 
anaesthesia practice was also explored as a possible risk factor for addiction. Finally, a 
comparison was made of the prevalence in non-specialists, training specialists (registrars), 
and specialist anaesthesiologists. We postulated that the incidence of substance use would 
be similar in all groups.  
 
Methods 
This study was conducted as a self-administered questionnaire, with closed-ended 
questions, and was only made available online, i.e. in a digital format. Approval was 
obtained from the Human Research Ethics Committee of the University of Cape Town (HREC 
190/2018) prior to distribution. The questionnaire used was available from the World 
Health Organization, namely the Alcohol, Smoking and Substance Involvement Screening 
Test (ASSIST). It was developed by the WHO in a primary health care setting, in collaboration 
with an international team of substance abuse researchers, and validated in seven 
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countries. 3 In the present study, the questionnaire was modified to include demographic 
data (Supplementary file 1). 
 
The questionnaire screens for use of tobacco products, alcohol, cannabis, cocaine, 
amphetamine-type stimulants, sedatives, hallucinogenics, inhalants, opioids and ‘other’ 
drugs. Examples of each category of substance are listed in the questionnaire. These were 
altered slightly for the South African context. ASSIST identifies lifetime use (i.e. use of the 
substance at any time in a practitioner’s life), as well as use in the previous three months. A 
risk score (low-, moderate-, or high risk) is then determined for each category of substance, 
based only upon use in the previous three months.  
 
The questionnaire is comprised of eight questions: question one examines lifetime use; 
question two examines frequency of use in the past three months; question three asks 
about urge or desire to use a substance; question four explores the frequency of social, 
legal, health or financial problems related to drug use; question five examines interference 
with responsibilities; question six asks whether anyone has ever expressed concern about 
usage; question seven asks about any attempt to stop or reduce substance use; and 
question eight asks about injection of substances. In addition to the physical use of a 
substance, the urge to use a substance (question three) has been postulated to be 
consistent with more frequent use, a previous problem with the substance, or a stronger 
potential for addiction.  
 
Scoring is done per category by adding the scores of questions two through seven. Question 
eight is not included in the scoring but is used as an indicator of risk. For all substances apart 
from alcohol, a score 0-3 indicates low risk, 4-26 indicates moderate risk (“likely to indicate 
hazardous or harmful substance use”), and greater than 27 high risk (“likely to indicate 
substance dependence”). Low risk alcohol use scores 0-10, moderate risk 11-26, and high 
risk greater than 27. ASSIST recommends no treatment for low risk scores, a brief 
intervention for moderate risk users, and specialist referral for high risk users. 4 Since our 
questionnaire was administered anonymously, no intervention could be provided. However, 
at the conclusion of the questionnaire, the respondent could see their risk score and 
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category with a brief explanation, as calculated online. Contact details for drug and alcohol 
help lines, as well as the SASA Wellness team, were provided. 
The questionnaire was run for ten days surrounding the 2018 South African Society of 
Anaesthesiologists (SASA) congress. Participants were recruited via a public link made 
available on email sent to all SASA members before the congress, as well as electronic 
distribution via a web-based link at the congress, on social media. Although not specifically 
validated for self-completion, it was felt that this method would better assure anonymity. 
The email was sent out once, with one follow-up/reminder five days later. The link to the 
questionnaire was then closed after ten days, allowing no further recruitment. 
 
Data was captured using “REDCap”, which is a secure web application for building and 
managing online surveys and databases, specifically designed for research studies. The 
REDCap system is run by SAFE SURGERY and ANSA.   
 
All anaesthesia practitioners who were doctors practicing in South Africa, were eligible. 
Specialist-, trainee-, and non-specialist Anaesthesiologists were included. The SASA email 
database was used. The demographic data distinguished between state- versus private 
practice. Work environment, drug handling, and stressors were postulated to differ in the 
two settings, which could influence substance use patterns. The prevalence of substance 
use was postulated to vary according to the length of exposure to both work environment 
stress, as well as access to drugs. Therefore, the number of years in practice was also 
captured. The prevalence of substance use in male and female practitioners was also 
recorded.  
 
Demographic variables were all categorical and were summarised using frequency tables 
and bar charts. ASSIST scores were categorised as defined in the questionnaire manual, and 
summarised overall and per stratification variable using frequency tables and percentages. 
Where comparisons of proportions between groups were possible, Pearson’s chi square 
tests or Fisher’s exact tests were conducted, as appropriate. If more than 25% of expected 
cell counts were less than five, Fisher’s exact p values were reported. Incomplete responses 
were treated as voluntary withdrawal and were discarded from the data set. A p value <0.05 





Participants eligible for the study were doctors currently practicing anaesthesia in South 
Africa. This included specialists, trainee specialists and non-specialists. A total of 1961 SASA 
members received the email link. In addition, 113 non-members were exposed to the link, 
via social media and during attendance of sessions, at the congress. Therefore, the total 
number of potential respondents was 2074. The number of respondents was 434, which 
gave a response rate of 20.9%, and a margin of error of 4.18%. Incomplete questionnaires 
(n=38) and non-South African practitioners were excluded (n=20), as well as respondents 
who did not indicate their nationality (n=12). The total number of analysed responses was 
364, as shown in Figure 1. There were 168 female respondents (46.7%) and 192 males 




Respondents were stratified according to qualification: specialists (71.7%), trainee 
specialists (18.4%), and general practitioners or medical officers (9.9%) practicing 
anaesthesia. Forty four percent of the respondents had had more than 15 years of 













years. Fifty five percent of respondents were from private practice and 45% from state 
hospitals. 
 
The lifetime use of all agents investigated, in the order listed in the questionnaire, is shown 
in Table I. Figure 2 is a histogram summarising this information. 
 
Table I –  Lifetime use of agents  
 N/364 % of users of 
each agent 
(CI) 
Tobacco products (cigarettes, chewing tobacco, cigars, snus etc.) 153 42.3% (37.3-
47.4) 
Alcoholic beverages (beer, wine, spirits, etc.) 336 92.8% (89.7-
95.1) 
Cannabis (marijuana, pot, grass, hash, edibles etc.) 123 34.7% (30.0-
39.8) 
Cocaine (coke, crack, etc.) 12 3.4% (2.0-5.8) 
Amphetamine type stimulants (speed, diet pills, ecstasy, 
methylphenidate/Ritalin, Concerta etc.) 
53 15.1% (11.7-
19.2) 
Inhalants (nitrous, glue, petrol, paint thinner, etc.) 9 2.6% (1.4-4.8) 
Sedatives or Sleeping Pills (Valium, Zopiclone, Zolpidem etc.) 123 34.4% (29.6-
39.4) 
Hallucinogens (LSD, acid, mushrooms, PCP, ketamine, etc.) 19 5.4% (3.5-8.3) 
Opioids (heroin, morphine, methadone, fentanyl, sufentanil codeine, etc.) 12 3.4% (2.0-5.9) 
Other (e.g. Propofol) 2 0.6% (0.2-2.0)  
 





A detailed description of substances used in the previous three months, shown as a 
percentage of users of the individual agent, as well as of the total sample, appears in Table 
II. Only alcohol fell into the high-risk category, with 1% of users displaying high risk 
behaviour (n=3). Moderate risk usage was highest for sedatives (12.6%) and alcohol (12.1%). 
The most commonly used substance was alcohol (n=310), followed by sedatives (n=74).  
 






Low risk Moderate risk High risk 
N 
% of users 
of each 
agent 
% of total 
sample 
N 
% of users 
of each 
agent 
% of total 
sample 
N 
% of users 
of each 
agent 










(0.4 to 2.8) 
25 86.2 
6.9 (4.7 to 
9.9) 
0 0.0 


























2.2 (1.1 to 
4.3) 
0 0.0 
0.0 (0 to 
1.0) 
0 0.0 0.0 
Cocaine 






0.3 (0 to 
1.5) 
0 0.0 
0.0 (0 to 
1.0) 









2.2 (1.1 to 
4.3) 
4 33.3 
1.1 (0.4 to 
2.8) 













0 0.0 0.0 
Opioids 





1.1 (0.4 to 
2.8) 
3 42.9 
0.8 (0.3 to 
2.4) 
0 0.0 0.0 
*amph = amphetamine 
 
The overall prevalence of urge to use a substance in practitioners using a particular agent, is 
shown in Table III. There was a statistically significantly higher prevalence of urge to use 
alcohol in those who had been in practice 5-10 years, when compared with all other 
groupings of years of experience (p=0.002). Females were more likely to experience an urge 
to use alcohol than males (p=0.010). The urge to use sedatives was also significantly higher 
in non-specialists than in specialists (p=0.016). Detailed data is available in Supplementary 
file 2. 
 
Table III –  Overall prevalence of urge  
 
Urge to use substance (N)  
% of each agent, (CI) 
Tobacco 25 
86.2% (69.4 to 94.5) 
Alcohol  160 
50.5% (45.0 to 55.9) 
Cannabis  0  
0.0% (0 to 32.4) 
Cocaine 0  
0.0% (0 to 79.3) 
Amphetamine 3  
25.0% (8.9 to 53.2) 
Sedative 41 
55.4% (44.1 to 66.2) 
Opioids 2 
28.6% (8.2 to 64.1) 
% = percentage of current users of the individual substance experiencing an urge to use the substance 
 
With respect to secondary outcomes, there was no statistically significant difference 
between the prevalence of male and female users of any substance. There were also no 
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differences between the proportions of practitioners in private- versus state hospitals, using 
any of the substances, or in substance use according to number of years of experience.  
 
Discussion 
This study examined the prevalence of lifetime- and previous three-month usage of various 
potentially addictive substances, by a total of 364 male and female anaesthesia 
practitioners of varying years of experience. A WHO-validated questionnaire, ASSIST, was 
used, and practitioners categorised as low-, moderate-, or high risk.  
 
With respect to lifetime use, the five most commonly used agents were alcohol, tobacco 
products, cannabis, sedatives and amphetamine type stimulants. Risk categories were 
assigned on the basis of questionnaire scores for substance use during the previous three 
months. Most commonly used were alcohol, sedatives, tobacco, and amphetamines. The 
majority of alcohol users were low risk. Practitioners at moderate risk used sedatives, 
alcohol, tobacco, and amphetamines. The knowledge of the latter scores would make it 
possible for these practitioners to self-refer for a brief intervention. Alcohol was the only 
substances with any high-risk use (n=3). These practitioners could self-refer for specialist 
treatment.  
 
The prevalence of opioid use was low (n=7), although this is likely an underestimate. Opioid 
dependence is particularly devastating in anaesthesia, and re-integration into the workplace 
is problematic. 1 The United States is currently battling a worsening opioid crisis, 5 
particularly fentanyl use. It is possible that this international trend may impact South Africa 
in the next few years. Our baseline data may provide valuable information to display a 
change in usage patterns within the profession in the future, if indeed opioid use becomes 
more common. 
 
The finding of an increased urge to use a substance, in practitioners of 5-10 years’ 
experience, in women, and on non-specialists, may be helpful in identifying psychological 




With respect to secondary outcomes, it was noteworthy that there was a similar prevalence 
of substance use in male and female practitioners, and in those working in the private 
practice or state hospital environment. There was inadequate statistical power to establish 
the relationship between years of experience, or the association between the level of 
qualification of the practitioner, and substance use. 
 
There are no data available to provide a comparison of the incidence of substance use in 
South African anaesthesia practitioners and those in other countries. A retrospective survey 
conducted in 2002 found the prevalence of drug abuse or dependence in 133 
anaesthesiology training programmes in the USA, to be 1.0-1.6%, with a higher prevalence 
in trainee specialist anaesthesiologists. A national survey of anaesthesiologists in France in 
2004 6 found a prevalence of 59.0% for alcohol use, 41.0% for tranquillisers and hypnotics, 
6.3% for cannabis, 5.5% for opiates and 1.9% for stimulants. Our data showed a higher 
overall prevalence of use of alcohol and stimulants, and less cannabis and opioid use. 
 
Amongst the general population, substance use disorders have a higher prevalence in South 
Africa than in European countries, with a lifetime usage of 13.3%. 7 Although anaesthesia 
practitioners are not representative of the South African population with respect to age, 
gender, and average income, we also quote for interest the known prevalence for alcohol 
and tobacco use in the general population. The prevalence of lifetime use of alcohol, the 
most commonly misused substance in South Africa, is 25%. Fourteen percent of the 
population has lifetime diagnosis of alcohol abuse and/or dependence. 7 This is similar to 
the prevalence found in our questionnaire of 12.9% of moderate- and high-risk users 
amongst anaesthesia practitioners, and comparable to developed countries. Tobacco use 
was found to be lower than in the general population; 8% versus 17.6% respectively. 8 
 
There are several limitations to this study. The response rate for the survey was low 
(20.9%). Although the margin of error of 4.18% is acceptable, the sample was not randomly- 
but rather self-selected, and the sensitive nature of the electronic survey is likely to have 
introduced bias, and an under-estimate of the prevalence of substance use. It is 
theoretically plausible that respondents to a sensitive topic which includes substance abuse, 
particularly if the information could potentially result in loss of employment or license to 
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practice, would not be truthful in their responses to a detailed questionnaire. However, 
there is evidence that there is little response bias if the questionnaire is anonymous, 9 and 
the risk of non-response to an emailed link should be offset against the benefit of 
anonymity.  
 
Our study could have been biased towards obtaining information from physicians with 
access to the internet, smart phone applications, Twitter accounts, and an active e-mail 
address. However, this was not expected to be a significant limitation, considering the 
general easy accessibility and widespread use of email and social media. Response rates to 
emailed or web-based surveys are comparable to a mail hard copy survey10 
 
The survey did not include doses of drugs which had been appropriately prescribed by a 
physician for a valid diagnosis, that might be used in excessive doses. However, based upon 
published literature, drugs prescribed and accessed via a treating physician, as opposed to 
self-prescription, are unlikely to be a major source of abuse. These therapeutic doses were 
therefore excluded by the questionnaire, to simplify the data collected.  
 
A sign of potential drug abuse in the workplace is a willingness to remain at work, to take 
extra shifts or to stay late (in order to increase access to drugs). 11 It was therefore a 
concern that running the survey during a congress might miss the users who had elected to 
stay at work and forgo the congress in order to improve access to drugs. This was addressed 
by also emailing the survey to SASA members.  
 
The ASSIST questionnaire classifies drugs in broad categories. It is therefore possible that 
the respondents may not have remembered or listed a substance that was not included in 
the list of examples. As many as possible common examples were listed, without making the 
survey too detailed. While this research aimed to report the prevalence of substance use, it 





This self-administered WHO questionnaire shows that the prevalence of lifetime use of both 
alcohol and sedatives by South African anaesthesia practitioners is of major concern. The 
overall use of alcohol exceeds that of the South African general population, and of 
anaesthesia practitioners internationally. A significant proportion of practitioners were 
assessed according to their previous 3 months’ use to be at moderate risk, implying the 
likelihood of hazardous or harmful substance use. Although opioid use was low compared 
with other substances, the 1.1% prevalence may be an underestimate. Factors such as 
gender and practice setting appear to have little impact on substance use patterns. It is 
therefore our recommendation that wellness efforts be aimed at all practitioners of 
anaesthesia. The impact on the lives of substances users, their families, patients and 
colleagues is often devastating. This study may be regarded as the first step towards 
addressing the problem, namely the acknowledgement that it exists.    
 
 Other information 
I declare that I have no financial or personal relationship(s) which may have inappropriately 
influenced me in writing this paper. 
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Supplementary File 1 – Questionnaire 





Thank you for participating in this important MMed study looking at the Incidence of Substance 
Abuse amongst Anaesthetists in South Africa. There is limited international data on this subject, 
and little to no data on South African anaesthetists. 
 
 
Many of us know, or have known, a colleague who is suffering from substance addiction. Sadly, 
substance addiction can have a huge negative impact on patient care, work attendance and 




It is therefore vital that, as a fraternity, we identify the extent of this problem within our context 
and aim to help and support those who are suffering from its grip. Without fully appreciating the 
extent, however, we cannot adequately provide care and assistance to those who are suffering. 
 
 
By continuing with this survey, you are consenting to have your responses form part of a data 
set which will be used to describe the incidence of substance use amongst anaesthetists in 
South Africa. Your responses will be completely anonymous. The questionnaire is built using 
REDCap, a trusted research resource. All responses are automatically disconnected from the 
respondent, and there is no way to trace the data back to you. The data set itself is also 
password protected to ensure data protection. 
 
 
The survey is comprised of 13 questions or less. It should take you no longer than 5-10 
minutes to complete, depending on your responses. This research is supported by the 
Wellness Committee of SASA. 
 
 
To reiterate, there is absolutely no way to link your responses back to you, even if you have 
received this questionnaire via email. Absolute anonymity is ensured. 
 
 




Thank you for your participation. 
 
 





Co-Investigators : Dr Francois Roodt, Dr Marcin Nejthardt, Dr Paul Magni 
 
 
Department of Anaesthesia, University of Cape Town 
 
 









GP Anaesthetist/Medical Officer 
 
How long have you been practicing anaesthesia? 
 
< 5 years 
5 - 10 years 
10 - 15 years 
> 15 years 
 
What best describes your current anaesthetic practice? 
 
Private practice only 
State practice only 
Majority state practice with some private work (10 hours or less per week) 
Majority private practice with some state work (10 hours or less per week) 
 







Tobacco products (cigarettes,   
                                                                                                chewing tobacco, cigars, snoes 
etc.) 
 
Alcoholic beverages (beer, wine,   
 spirits, etc.) 
Cannabis (marijuana, pot, grass,   
 hash, edibles etc.) 
Cocaine (coke, crack, etc.)    
Amphetamine type stimulants   




Inhalants (nitrous, glue, petrol,   
 paint thinner, etc.) 
Sedatives or Sleeping Pills   
                                                                                                      (Valium, Zopiclone, Zolpidem 
etc.) 
Hallucinogens (LSD, acid, 
mushrooms, PCP, ketamine, etc.) 
Opioids (heroin, morphine,   
 methadone, fentanyl, sufentanil 
codeine, etc.) 
 
Other (e.g. Propofol)    
 
If other, please specify 
 







Never Once or twice Weekly Daily or almost daily 
Tobacco products (cigarettes,                                                                                                                          
                                                                                                                chewing tobacco, cigars, snoes 
etc.) 
 
Alcoholic beverages (beer, wine,                                                                                                                          
 spirits, etc.) 
Cannabis (marijuana, pot, grass,                                                                                                                          
 hash, edibles etc.) 
Cocaine (coke, crack, etc.)                                                                                                                           
Amphetamine type stimulants                                                                                                                          




Inhalants (nitrous, glue, petrol,                                                                                                                          
 paint thinner, etc.) 
Sedatives or Sleeping Pills                                                                                                                          
                                                                                                                      (Valium, Zopiclone, Zolpidem 
etc.) 
Hallucinogens (LSD, acid, 
mushrooms, PCP, Ketamine, 
etc.) 
Opioids (heroin, morphine, 
methadone, fentanil, sufentanil, 
codeine, etc.) 
 
Other (e.g. Propofol)                                                                                                                           
 
If other, please specify 
 







During the past three months, how often have you had Never 
a strong desire or urge to use tobacco products Once or twice 
(cigarettes, chewing tobacco, cigars, snoes etc.) Monthly 
Weekly 
Daily or almost daily 
 
During the past three months, how often has your use Never 
of the following led to health, social, legal or Once or twice 
financial problems? tobacco products (cigarettes, Monthly 
chewing tobacco, cigars, snoes etc.) Weekly 
Daily or almost daily 
 
During the past three months, how often have you Never 
failed to do what was normally expected of you Once or twice 
because of your use of tobacco products (cigarettes, Monthly 
chewing tobacco, cigars, snoes etc.)? Weekly 








During the past three months, how often have you had Never 
a strong desire or urge to use  alcoholic beverages Once or twice 
(beer, wine, spirits, etc.)? Monthly 
Weekly 
Daily or almost daily 
 
During the past three months, how often has your use Never 
of alcoholic beverages (beer, wine, spirits, etc.) Once or twice 
led to health, social, legal or financial problems? Monthly 
Weekly 
Daily or almost daily 
 
During the past three months, how often have you Never 
failed to do what was normally expected of you Once or twice 
because of your use of alcoholic beverages (beer, Monthly 
wine, spirits, etc.)? Weekly 








During the past three months, how often have you had Never 
a strong desire or urge to use cannabis (marijuana, Once or twice 
pot, grass, hash, edibles etc.)? Monthly 
Weekly 
Daily or almost daily 
 
During the past three months, how often has your use Never 
of cannabis (marijuana, pot, grass, hash, edibles Once or twice 
etc.) led to health, social, legal or financial Monthly 
problems? Weekly 
Daily or almost daily 
 
During the past three months, how often have you Never 
failed to do what was normally expected of you Once or twice 
because of your use of cannabis (marijuana, pot, Monthly 
grass, hash, edibles etc.)? Weekly 








During the past three months, how often have you had Never 
a strong desire or urge to use cocaine (coke, crack, Once or twice 
etc.) Monthly 
Weekly 
Daily or almost daily 
 
During the past three months, how often has your use Never 
of cocaine (coke, crack, etc.) led to health, Once or twice 
social, legal or financial problems? Monthly 
Weekly 
Daily or almost daily 
 
During the past three months, how often have you Never 
failed to do what was normally expected of you Once or twice 
because of your use of cocaine (coke, crack, etc.)? Monthly 
Weekly 








During the past three months, how often have you had Never 
a strong desire or urge to use amphetamine type Once or twice 
stimulants (speed, diet pills, ecstasy, Monthly 
methylphenidate/Ritalin, Concerta etc.) Weekly 
Daily or almost daily 
 
During the past three months, how often has your use Never 
of amphetamine type stimulants (speed, diet pills, Once or twice 
ecstasy, methylphenidate/ Ritalin, Concerta etc.) Monthly 
led to health, social, legal or financial problems? Weekly 
Daily or almost daily 
 
During the past three months, how often have you Never 
failed to do what was normally expected of you Once or twice 
because of your use of amphetamine type stimulants Monthly 
(speed, diet pills, ecstasy, methylphenidate/ Weekly 








During the past three months, how often have you had Never 
a strong desire or urge to use inhalants (nitrous, Once or twice 
glue, petrol, paint thinner, etc.) Monthly 
Weekly 
Daily or almost daily 
 
During the past three months, how often has your use Never 
of inhalants (nitrous, glue, petrol, paint thinner, Once or twice 
etc.) led to health, social, legal or financial Monthly 
problems? Weekly 
Daily or almost daily 
 
During the past three months, how often have you Never 
failed to do what was normally expected of you Once or twice 
because of your use of inhalants (nitrous, glue, Monthly 
petrol, paint thinner, etc.)? Weekly 








During the past three months, how often have you had Never 
a strong desire or urge to use sedatives  or sleeping Once or twice 
pills (Valium, Zopiclone, Zolpidem, etc.) Monthly 
Weekly 
Daily or almost daily 
 
During the past three months, how often has your use Never 
of sedatives or sleeping pills (Valium, Zopiclone, Once or twice 
Zolpidem etc.) led to health, social, legal or Monthly 
financial problems? Weekly 
Daily or almost daily 
 
During the past three months, how often have you Never 
failed to do what was normally expected of you Once or twice 
because of your use of sedatives or sleeping pills Monthly 
(Valium, Zopiclone, Zolpidem, etc.)? Weekly 
Daily or almost daily 







During the past three months, how often have you had Never 
a strong desire or urge to use hallucinogens (LSD, Once or twice 
acid, mushrooms, PCP, ketamine, etc.) Monthly 
Weekly 
Daily or almost daily 
 
During the past three months, how often has your use Never 
of hallucinogens (LSD, acid, mushrooms, PCP, Once or twice 
ketamine, etc.) led to health, social, legal or Monthly 
financial problems? Weekly 
Daily or almost daily 
 
During the past three months, how often have you Never 
failed to do what was normally expected of you Once or twice 
because of your use of hallucinogens (LSD, acid, Monthly 
mushrooms, PCP, ketamine, etc.)? Weekly 








During the past three months, how often have you had Never 
a strong desire or urge to use opioids (heroin, Once or twice 
morphine, methadone, fentanyl, sufentanil codeine, Monthly 
etc.) Weekly 
Daily or almost daily 
 
During the past three months, how often has your use Never 
of opioids (heroin, morphine, methadone, fentanyl, Once or twice 
sufentanil, codeine, etc.) led to health, social, Monthly 
legal or financial problems? Weekly 
Daily or almost daily 
 
During the past three months, how often have you Never 
failed to do what was normally expected of you Once or twice 
because of your use of opioids (heroin, morphine, Monthly 
methadone, fentanyl, sufentanil, codeine, etc.)? Weekly 








During the past three months, how often have you had Never 
a strong desire or urge to use other drugs (e.g. Once or twice 
Propofol) Monthly 
Weekly 
Daily or almost daily 
 
If other, please specify 
 
 
During the past three months, how often has your use Never 
of other drugs (e.g. Propofol) led to health, Once or twice 
social, legal or financial problems? Monthly 
Weekly 
Daily or almost daily 
 
If other, please specify 
 
 
During the past three months, how often have you Never 
failed to do what was normally expected of you Once or twice 
because of your use of other drugs (e.g. Propofol)? Monthly 
Weekly 
Daily or almost daily 
 








Tobacco products (cigarettes, chewing tobacco, No, Never 
cigars, snoes etc.) Yes, in the past 3 months 
Yes, but not in the past 3 months 
 
Alcoholic beverages (beer, wine, spirits, etc.) No, Never 
Yes, in the past 3 months 
Yes, but not in the past 3 months 
 
Cannabis (marijuana, pot, grass, hash, edibles etc.) No, Never 
Yes, in the past 3 months 
Yes, but not in the past 3 months 
 
Cocaine (coke, crack, etc.) No, Never 
Yes, in the past 3 months 
Yes, but not in the past 3 months 
 
Amphetamine type stimulants (speed, diet pills, No, Never 
ecstasy, methylphenidate/Ritalin, Concerta etc.) Yes, in the past 3 months 
Yes, but not in the past 3 months 
 
Inhalants (nitrous, glue, petrol, paint thinner, No, Never 
etc.) Yes, in the past 3 months 
Yes, but not in the past 3 months 
 
Sedatives or Sleeping Pills (Valium, Zopiclone, No, Never 
Zolpidem etc.) Yes, in the past 3 months 
Yes, but not in the past 3 months 
 
Hallucinogens (LSD, acid, mushrooms, PCP, ketamine, No, Never 
etc.) Yes, in the past 3 months 
Yes, but not in the past 3 months 
 
Opioids (heroin, morphine, methadone, fentanyl, No, Never 
sufentanil, codeine, etc.) Yes, in the past 3 months 
Yes, but not in the past 3 months 
 
Other (e.g. Propofol) No, Never 
Yes, in the past 3 months 
Yes, but not in the past 3 months 
 
If other, please specify 
 








Tobacco products (cigarettes, chewing tobacco, No, Never 
cigars, snoes etc.) Yes, in the past 3 months 
Yes, but not in the past 3 months 
 
Alcoholic beverages (beer, wine, spirits, etc.) No, Never 
Yes, in the past 3 months 
Yes, but not in the past 3 months 
 
Cannabis (marijuana, pot, grass, hash, edibles etc.) No, Never 
Yes, in the past 3 months 
Yes, but not in the past 3 months 
 
Cocaine (coke, crack, etc.) No, Never 
Yes, in the past 3 months 
Yes, but not in the past 3 months 
 
Amphetamine type stimulants (speed, diet pills, No, Never 
ecstasy, methylphenidate/Ritalin, Concerta etc.) Yes, in the past 3 months 
Yes, but not in the past 3 months 
 
Inhalants (nitrous, glue, petrol, paint thinner, No, Never 
etc.) Yes, in the past 3 months 
Yes, but not in the past 3 months 
 
Sedatives or Sleeping Pills (Valium, Zopiclone, No, Never 
Zolpidem etc.) Yes, in the past 3 months 
Yes, but not in the past 3 months 
 
Hallucinogens (LSD, acid, mushrooms, PCP, ketamine, No, Never 
etc.) Yes, in the past 3 months 
Yes, but not in the past 3 months 
 
Opioids (heroin, morphine, methadone, fentanyl, No, Never 
sufentanil, codeine, etc.) Yes, in the past 3 months 
Yes, but not in the past 3 months 
 
Other (e.g. Propofol) No, Never 
Yes, in the past 3 months 
Yes, but not in the past 3 months 
 
If other, please specify 
 







Have you ever used any drug by injection? No, Never 
(NON-MEDICAL USE ONLY) Yes, in the past 3 months 
Yes, but not in the past 3 months 
 
What was your pattern of injecting during this Once weekly or less 
period? Fewer than 3 days in a row 
More than once per week 










Your risk is: Low 
 
Your risk is: Medium 
 





Your risk is: Low 
 
Your risk is: Medium 
 





Your risk is: Low 
 
Your risk is: Medium 
 





Your risk is: Low 
 
Your risk is: Medium 
 





Your risk is: Low 
 
Your risk is: Medium 
 





Your risk is: Low 
Thank you for taking the time to complete this questionnaire. Based on your responses, your  
risk levels are as follows: (please note, these are for your feedback only, and are anonymous. They are not 





Your risk is: Medium 
 





Your risk is: Low 
 
Your risk is: Medium 
 





Your risk is: Low 
 
Your risk is: Medium 
 





Your risk is: Low 
 
Your risk is: Medium 
 





Your risk is: Low 
 
Your risk is: Medium 
 
Your risk is: High 
 
What do your scores mean?Low: You are at low risk of health and other problems from your current pattern of 
use.Moderate: You are at risk of health and other problems from your current pattern of substance use.High: You are 
at high risk of experiencing severe problems (health, social , financial, legal, 
relationship) as a result of your current pattern of use and are likely to be dependent  
 
 
If you would like to speak to someone about your substance use, or your risks, or would like to 
reach out for help, please contact the SASA Wellness Team 
 
 
Name Telephone No Email 
Ms Natalie Zimmelma 082 331 7846 ceo@sasaweb.com 
Dr Caroline Lee 082 777 2136 dreamdocsa@gmail.com 
Dr Allan Hold 082 655 7792 holdfam@iafrica.com 
Dr Bhavika Daya 083 787 1177 bhavikadaya@gmail.com 
Dr Megan Jaworska 082 371 2383 madzia2908@gmail.com 
 





c) SANCA national 




d) Substance use helpline 
Tel: 0800121314 
SMS: 32312 






Supplementary File 2 
 Qualification P value (Chi square 
or Fisher’s exact) Specialist  Registrar  GP or MO 
Positive urge Positive urge Positive urge  
Tobacco  N 13 6 6 0.194 
% of each agent 76.5% 100.0% 100.0% 
Alcohol  N 117 28 15 0.932 
% of each agent 50.0% 52.8% 50.0% 
 
 
Cannabis  N 0 0 0 - 
% of each agent 0.0% 0.0% 0.0% 
Cocaine  N 0 0 0 - 
% of each agent 0.0% 0.0%  
Amph*  N 1 2 0 0.532 
% of each agent 14.3% 40.0% 0.0% 
Sedatives  N 26 10 5 0.016 
% of each agent 46.4% 76.9% 100.0% 
Opioids  N 1 1 0 1.000 
% of each agent 25.0% 33.3% 0.0% 
 
 Number of years in practice P value (Chi 
square or 
Fisher’s exact) 
< 5 years 5-10 years 10-15 years >15 years 
Positive urge Positive urge Positive urge Positive urge  
Tobacco  N 4 6 7 8 0.658 
% of each agent 80.0% 85.7% 100.0% 80.0% 
Alcohol  N 22 52 30 56 0.002 
% of each agent 51.2% 65.0% 57.7% 39.4% 
Cannabis  N 0 0 0 0 - 
% of each agent 0.0% 0.0% 0.0% 0.0% 
Cocaine N 0 0 0 0 - 
% of each agent 0.0% 0.0% 0.0% 0.0% 
Amph* N 1 1 0 1 - 
% of each agent 25.0% 25.0% 0.0% 50.0% 
Sedative  N 7 10 8 16 0.230 
% of each agent 87.5% 55.6% 57.1% 47.1% 
Opioids  N 0 1 1 0 - 
 
 Gender P value (Fisher’s exact) 
male female 
Positive urge Positive urge  
Tobacco N 17 8 1.000 
% of each agent 85.0% 88.9% 
Alcohol N 76 83 0.010 
% of each agent 43.9% 58.5% 
Cannabis N 0 0 - 
% of each agent 0.0% 0.0% 
Cocaine N 0 0 - 
% of each agent 0.0% 0.0% 
Amph* N 1 2 0.236 
 
 
% of each agent 12.5% 50.0% 
Sedative N 19 22 1.000 
% of each agent 54.3% 56.4% 
Opioids N 1 1 1.000 
 
 Private or mostly private State or mostly state P value (Fisher’s exact) 
Positive urge Positive urge  
Tobacco N 14 11 0.268 
% of each agent 77.8% 100.0% 
Alcohol N 83 77 0.113 
% of each agent 46.4% 55.8% 
Cannabis N 0 0 - 
% of each agent 0.0% 0.0% 
Cocaine N 0 0 - 
% of each agent 0.0% 0.0% 
Amph* N 1 2 1.000 
% of each agent 25.0% 25.0% 
Sedative  N 21 20 0.643 
% of each agent 52.5% 58.8% 
Opioids  N 1 1 1.000 
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